Targeted therapy on breast cancer
Year: 2024
Type: article
Abstract: Breast cancer is the most common cause of cancer in women and the second most common cause of cancer death in women in the U.S. Breast cancer refers to cancers originating from breast tissue, most commonly from the inner lining of milk ducts or the lobules that supply the ducts with milk. Cancer develops if the immune system is not working properly and / or the amount of cells produced is too great for the immune system to eliminate. The rate of DNA and RNA mutations can be too high under some conditions such as; unhealthy environment (due to radiation, chemicals, etc.), poor diet (unhealthy cell environment) people with genetic predispositions to mutations and people of advanced age (above 80). There are different kinds of breast cancer which are Non-Invasive Breast Cancer, Invasive Breast Cancer, Lobular carcinoma in situ, Ductal carcinoma in situ, Infiltrating ductal carcinoma. Targeted drug therapy uses medicines that are directed at (target) proteins on breast cancer cells that help them grow, spread, and live longer. Targeted drugs work to destroy cancer cells or slow their growth. They have side effects different from chemotherapy. Some targeted therapy drugs, for example, monoclonal antibodies, work in more than one way to control cancer cells and may also be considered immunotherapy because they boost the immune system. Like chemotherapy, these drugs enter the bloodstream and reach almost all areas of the body, which makes them useful against cancers that have spread to distant parts of the body.
Author: Mukta Raut*, Shivprasad Deokar, Dr. Kawade Rajendra
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6911752386
FWCI:
Cites:
Cited by:
Related to: